Corvus Pharmaceuticals, Inc.

Equities

CRVS

US2210151005

Biotechnology & Medical Research

Delayed Nasdaq Other stock markets 01:27:22 2024-04-19 pm EDT			5-day change	1st Jan Change
1.41 ^USD	0.00%		-7.84%	-19.89%

Apr. 09	Corvus Pharmaceuticals, Inc. Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis	CI
Mar. 20	Oppenheimer Trims Corvus Pharmaceuticals Price Target to $7 From $8, Maintains Outperform Rating	MT

Corvus Pharmaceuticals to Present at the Jefferies 2020 Virtual Healthcare Conference

May 27, 2020 at 08:01 am EDT

BURLINGAME, Calif., May 27, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies and the utilization of novel biomarkers to enhance patient selection, today announced that the company will present at the Jefferies 2020 Virtual Healthcare Conference. The presentation is scheduled for Tuesday, June 2, 2020 from 2:00 – 2:25 pm Eastern Time.

A webcast of the presentation will be available live and for 30 days following the event. The webcast may be accessed via the investor relations section of the Corvus website.

About Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies and the utilization of novel biomarkers to enhance patient selection. Corvus’ lead product candidates are ciforadenant (CPI-444), a small molecule inhibitor of the A2A receptor, and CPI-006, a humanized monoclonal antibody directed against CD73 that exhibits immunomodulatory activity and activation of immune cells. These product candidates are being studied in ongoing Phase 1b/2 and Phase 1/1b clinical trials in patients with a wide range of advanced solid tumors. Ciforadenant is being evaluated in a successive expansion cohort Phase 1b/2 trial examining its activity both as a single agent and in combination with an anti-PD-L1 antibody. CPI-006 is being evaluated in a multicenter Phase 1/1b clinical trial as a single agent, in combination with ciforadenant and pembrolizumab. The Company’s third clinical program, CPI-818, an oral, small molecule drug that has been shown to selectively inhibit ITK, is in a multicenter Phase 1/1b clinical trial in patients with several types of T-cell lymphomas. For more information, visit www.corvuspharma.com.

INVESTOR CONTACT:
Leiv Lea
Chief Financial Officer
Corvus Pharmaceuticals, Inc.
+1-650-900-4522
llea@corvuspharma.com

MEDIA CONTACT:
Sheryl Seapy
W2O pure
+1 213-262-9390
sseapy@purecommunications.com

Latest news about Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals, Inc. Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis	Apr. 09	CI
Oppenheimer Trims Corvus Pharmaceuticals Price Target to $7 From $8, Maintains Outperform Rating	Mar. 20	MT
Corvus Pharmaceuticals to Start Phase 1 Study of Atopic Dermatitis Treatment in Q2	Mar. 19	MT
Transcript : Corvus Pharmaceuticals, Inc., Q4 2023 Earnings Call, Mar 19, 2024	Mar. 19
Corvus Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 19	CI
Corvus Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 19	CI
Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data At the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases	Feb. 12	CI
Sector Update: Health Care Stocks Mixed in Afternoon Trading	Feb. 09	MT
Sector Update: Health Care Stocks Mixed Pre-Bell Friday	Feb. 09	MT
Corvus Pharmaceuticals Says Soquelitinib Received FDA Orphan Drug Designation	Feb. 09	MT
Corvus Pharmaceuticals Shares Rise on Orphan Drug Designation	Feb. 08	DJ
Corvus Pharmaceuticals, Inc. Appoints Jeffrey Arcara as Chief Business Officer	Feb. 06	CI
Corvus Pharmaceuticals Announces Demise of Edith P. Mitchell, Member of the Board of Directors	Jan. 23	CI
Corvus Pharmaceuticals, Inc. Presents New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial	Dec. 09	CI
Transcript : Corvus Pharmaceuticals, Inc., Q3 2023 Earnings Call, Nov 07, 2023	Nov. 07
Corvus Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
Corvus Pharmaceuticals Says Preclinical Data Showed Soquelitinib Was Active in Six Inflammatory, Immune Disease Models	Nov. 02	MT
Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to T Cell-Mediated Inflammatory and Immune Diseases	Nov. 01	CI
Oppenheimer Adjusts Corvus Pharmaceuticals Price Target to $8 From $7, Maintains Outperform Rating	23-09-11	MT
Oppenheimer Adjusts Corvus Pharmaceuticals Price Target to $8 From $7, Maintains Outperform Rating	23-09-07	MT
Transcript : Corvus Pharmaceuticals, Inc. - Special Call	23-09-07
Corvus Pharmaceuticals, Inc. Confirms Planned Initiation of Soquelitinib (CPI-818) Phase 3 Registrational Clinical Trial in Peripheral T Cell Lymphoma	23-09-07	CI
Corvus Completes FDA Meeting on Plans to Launch Phase 3 Cancer Trial; Shares Jump After-Hours	23-09-06	MT
Oppenheimer Initiates Coverage on Corvus Pharmaceuticals With Outperform Rating, $7 Price Target	23-08-18	MT
Transcript : Corvus Pharmaceuticals, Inc., Q2 2023 Earnings Call, Aug 08, 2023	23-08-08

Chart Corvus Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of ITK inhibition as a new approach to immunotherapy for a range of cancer and immune diseases. Its lead product candidate is soquelitinib, a selective, covalent inhibitor of ITK (interleukin 2 inducible T cell kinase) and is in a multi-center Phase 1/1b clinical trial in patients with various recurrent, malignant T cell lymphomas. Soquelitinib is designed to inhibit the proliferation of certain malignant T cells. Its second product candidate, ciforadenant, is an oral, small molecule antagonist of the A2A receptor for adenosine designed to disable a tumorâs ability to subvert attack by the immune system by blocking the binding of immunosuppressive adenosine in the tumor microenvironment to the A2A receptor. The Companyâs third product candidate is mupadolimab, a humanized monoclonal antibody that is designed to react with a specific site on CD73.

Sector

Biotechnology & Medical Research

Calendar

2024-05-07 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.41 USD

Average target price

7.5 USD

Spread / Average Target

+431.91%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
CORVUS PHARMACEUTICALS, INC.	-19.89%	69.14M
IQVIA HOLDINGS INC.	-2.09%	41.35B
LONZA GROUP AG	+42.15%	40.38B
MODERNA, INC.	+1.80%	39.05B
CELLTRION, INC.	-14.19%	26.67B
ICON PUBLIC LIMITED COMPANY	+1.65%	24.07B
ALNYLAM PHARMACEUTICALS, INC.	-24.64%	18.36B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.82%	11.68B
MEDPACE HOLDINGS, INC.	+21.19%	11.6B
UNITED THERAPEUTICS CORPORATION	+7.67%	11.15B

Other Biotechnology & Medical Research